Literature DB >> 20227041

Modulation of the vitamin D3 response by cancer-associated mutant p53.

Perry Stambolsky1, Yuval Tabach, Giulia Fontemaggi, Lilach Weisz, Revital Maor-Aloni, Zehava Siegfried, Zahava Sigfried, Idit Shiff, Ira Kogan, Moshe Shay, Eyal Kalo, Giovanni Blandino, Itamar Simon, Moshe Oren, Varda Rotter.   

Abstract

The p53 gene is mutated in many human tumors. Cells of such tumors often contain abundant mutant p53 (mutp53) protein, which may contribute actively to tumor progression via a gain-of-function mechanism. We applied ChIP-on-chip analysis and identified the vitamin D receptor (VDR) response element as overrepresented in promoter sequences bound by mutp53. We report that mutp53 can interact functionally and physically with VDR. Mutp53 is recruited to VDR-regulated genes and modulates their expression, augmenting the transactivation of some genes and relieving the repression of others. Furthermore, mutp53 increases the nuclear accumulation of VDR. Importantly, mutp53 converts vitamin D into an antiapoptotic agent. Thus, p53 status can determine the biological impact of vitamin D on tumor cells. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20227041      PMCID: PMC2882298          DOI: 10.1016/j.ccr.2009.11.025

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  55 in total

1.  WNT5A--target of CUTL1 and potent modulator of tumor cell migration and invasion in pancreatic cancer.

Authors:  S Ripka; A König; M Buchholz; M Wagner; B Sipos; G Klöppel; J Downward; Tm Gress; P Michl
Journal:  Carcinogenesis       Date:  2007-01-16       Impact factor: 4.944

2.  Conditional activation of FGFR1 in the prostate epithelium induces angiogenesis with concomitant differential regulation of Ang-1 and Ang-2.

Authors:  S F Winter; V D Acevedo; R D Gangula; K W Freeman; D M Spencer; N M Greenberg
Journal:  Oncogene       Date:  2007-02-12       Impact factor: 9.867

3.  Differential regulation of vitamin D receptor (VDR) by the p53 Family: p73-dependent induction of VDR upon DNA damage.

Authors:  Ramakrishna Kommagani; Vandana Payal; Madhavi P Kadakia
Journal:  J Biol Chem       Date:  2007-08-23       Impact factor: 5.157

4.  hTERT-immortalized prostate epithelial and stromal-derived cells: an authentic in vitro model for differentiation and carcinogenesis.

Authors:  Ira Kogan; Naomi Goldfinger; Michael Milyavsky; Merav Cohen; Igor Shats; Gabriele Dobler; Helmut Klocker; Bohdan Wasylyk; Maureen Voller; Tilly Aalders; Jack A Schalken; Moshe Oren; Varda Rotter
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

5.  Kallikrein 6 induces E-cadherin shedding and promotes cell proliferation, migration, and invasion.

Authors:  Britta Klucky; Regina Mueller; Ingeborg Vogt; Sibylle Teurich; Bettina Hartenstein; Kai Breuhahn; Christa Flechtenmacher; Peter Angel; Jochen Hess
Journal:  Cancer Res       Date:  2007-09-01       Impact factor: 12.701

Review 6.  Vitamin D signalling pathways in cancer: potential for anticancer therapeutics.

Authors:  Kristin K Deeb; Donald L Trump; Candace S Johnson
Journal:  Nat Rev Cancer       Date:  2007-09       Impact factor: 60.716

7.  Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells.

Authors:  Lilach Weisz; Alexander Damalas; Michalis Liontos; Panagiotis Karakaidos; Giulia Fontemaggi; Revital Maor-Aloni; Marina Kalis; Massimo Levrero; Sabrina Strano; Vassilis G Gorgoulis; Varda Rotter; Giovanni Blandino; Moshe Oren
Journal:  Cancer Res       Date:  2007-03-15       Impact factor: 12.701

Review 8.  Shaping genetic alterations in human cancer: the p53 mutation paradigm.

Authors:  Thierry Soussi; Klas G Wiman
Journal:  Cancer Cell       Date:  2007-10       Impact factor: 31.743

9.  Wide-scale analysis of human functional transcription factor binding reveals a strong bias towards the transcription start site.

Authors:  Yuval Tabach; Ran Brosh; Yossi Buganim; Anat Reiner; Or Zuk; Assif Yitzhaky; Mark Koudritsky; Varda Rotter; Eytan Domany
Journal:  PLoS One       Date:  2007-08-29       Impact factor: 3.240

10.  Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia.

Authors:  Aparna Raval; Stephan M Tanner; John C Byrd; Elizabeth B Angerman; James D Perko; Shih-Shih Chen; Björn Hackanson; Michael R Grever; David M Lucas; Jennifer J Matkovic; Thomas S Lin; Thomas J Kipps; Fiona Murray; Dennis Weisenburger; Warren Sanger; Jane Lynch; Patrice Watson; Mary Jansen; Yuko Yoshinaga; Richard Rosenquist; Pieter J de Jong; Penny Coggill; Stephan Beck; Henry Lynch; Albert de la Chapelle; Christoph Plass
Journal:  Cell       Date:  2007-06-01       Impact factor: 41.582

View more
  117 in total

Review 1.  MicroRNAs, wild-type and mutant p53: more questions than answers.

Authors:  Matthew Jones; Ashish Lal
Journal:  RNA Biol       Date:  2012-06-01       Impact factor: 4.652

Review 2.  Vitamin D and cancer: a review of molecular mechanisms.

Authors:  James C Fleet; Marsha DeSmet; Robert Johnson; Yan Li
Journal:  Biochem J       Date:  2012-01-01       Impact factor: 3.857

3.  Mutant p53 cooperates with ETS2 to promote etoposide resistance.

Authors:  Phi M Do; Lakshman Varanasi; Songqing Fan; Chunyang Li; Iwona Kubacka; Virginia Newman; Krishna Chauhan; Silvano Rakeem Daniels; Maurizio Boccetta; Michael R Garrett; Runzhao Li; Luis A Martinez
Journal:  Genes Dev       Date:  2012-04-15       Impact factor: 11.361

4.  Protein misinteraction avoidance causes highly expressed proteins to evolve slowly.

Authors:  Jian-Rong Yang; Ben-Yang Liao; Shi-Mei Zhuang; Jianzhi Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-13       Impact factor: 11.205

5.  Mutant p53 is a transcriptional co-factor that binds to G-rich regulatory regions of active genes and generates transcriptional plasticity.

Authors:  Timo Quante; Benjamin Otto; Marie Brázdová; Iva Kejnovská; Wolfgang Deppert; Genrich V Tolstonog
Journal:  Cell Cycle       Date:  2012-08-21       Impact factor: 4.534

6.  Mutant p53 regulates enhancer-associated H3K4 monomethylation through interactions with the methyltransferase MLL4.

Authors:  Homa Rahnamoun; Juyeong Hong; Zhengxi Sun; Jihoon Lee; Hanbin Lu; Shannon M Lauberth
Journal:  J Biol Chem       Date:  2018-06-28       Impact factor: 5.157

7.  Vitamin D-binding protein and pancreatic cancer: a nested case-control study.

Authors:  Marina R Piper; D Michal Freedman; Kim Robien; William Kopp; Helen Rager; Ronald L Horst; Rachael Z Stolzenberg-Solomon
Journal:  Am J Clin Nutr       Date:  2015-04-22       Impact factor: 7.045

8.  Pla2g16 phospholipase mediates gain-of-function activities of mutant p53.

Authors:  Shunbin Xiong; Huolin Tu; Madhusudhan Kollareddy; Vinod Pant; Qin Li; Yun Zhang; James G Jackson; Young-Ah Suh; Ana C Elizondo-Fraire; Peirong Yang; Gilda Chau; Mehrnoosh Tashakori; Amanda R Wasylishen; Zhenlin Ju; Hilla Solomon; Varda Rotter; Bin Liu; Adel K El-Naggar; Lawrence A Donehower; Luis Alfonso Martinez; Guillermina Lozano
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-14       Impact factor: 11.205

9.  Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway.

Authors:  William A Freed-Pastor; Hideaki Mizuno; Xi Zhao; Anita Langerød; Sung-Hwan Moon; Ruth Rodriguez-Barrueco; Anthony Barsotti; Agustin Chicas; Wencheng Li; Alla Polotskaia; Mina J Bissell; Timothy F Osborne; Bin Tian; Scott W Lowe; Jose M Silva; Anne-Lise Børresen-Dale; Arnold J Levine; Jill Bargonetti; Carol Prives
Journal:  Cell       Date:  2012-01-20       Impact factor: 41.582

10.  The activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteins.

Authors:  Saisai Wei; Hongbo Wang; Chunwan Lu; Sarah Malmut; Jianqiao Zhang; Shumei Ren; Guohua Yu; Wei Wang; Dale D Tang; Chunhong Yan
Journal:  J Biol Chem       Date:  2014-02-19       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.